AIM ImmunoTech announces exercise of warrants for $4.2 million proceeds

AIM ImmunoTech Inc. Common Stock

AIM ImmunoTech Inc. Common Stock

AIM

0.00
  • AIM ImmunoTech reached agreement with accredited investors to exercise outstanding warrants for 8,719,928 common shares at reduced exercise price of USD 0.48, generating about USD 4.2 million in gross proceeds.
  • Exercising holders will receive unregistered Replacement Warrants for up to 17,439,856 common shares at exercise price of USD 0.6, exercisable from effective date of stockholder approval with five-year term.
  • Net proceeds earmarked for working capital, general corporate purposes.
  • Closing expected on or about May 8, 2026, subject to customary conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080840PRIMZONEFULLFEED9716426) on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.